Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 ,inter alia, to consider and approve Unaudited standalone and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has informed the BSE that its Board of Directors will meet on Thursday, 29 January 2026. The main agenda is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31 December 2025 (Q3 FY26), in line with SEBI Listing Regulations. The company's trading window for designated persons remains closed from 1 January 2026 until 48 hours after the results are declared.
This is a routine regulatory filing ahead of the Q3 results announcement. No business or valuation impact for shareholders at this stage — actual numbers and any surprises will only emerge once the results are declared on or after 29 January 2026.